Patellar cartilage damage and why it needs more than symptom relief

Pain at the front of the knee — worse on stairs, after sitting for long periods, or when squatting — is one of the most common complaints seen in a knee clinic, yet it is also one of the most undertreated at source. In most cases, it originates from the cartilage on the underside of the kneecap (patella), where the joint surface meets the femoral trochlea and absorbs compressive loads that can exceed several times body weight during everyday activities.

The damage itself spans a wide spectrum. Chondromalacia patellae describes the earliest changes — softening, blistering, and fissuring of the cartilage surface. At the more severe end, focal full-thickness lesions classified as ICRS Grade III or IV involve loss of cartilage extending to or through the subchondral bone. Acute patellar dislocations, particularly in younger patients, can shear away cartilage in a single event; osteochondritis dissecans (OCD) of the patella represents a further distinct subgroup. All of these conditions share one feature: the cartilage does not spontaneously regenerate once it is lost.

Physiotherapy, hyaluronic acid injections, and corticosteroids can reduce pain and inflammation, but none of them address the structural deficit. They manage the environment around a defect rather than the defect itself. When imaging confirms cartilage loss, a treatment that targets the tissue directly — rather than the symptoms it generates — represents a meaningfully different category of intervention.

Who is a suitable candidate for ChondroFiller injection at the kneecap

Three conditions determine whether a patient is suitable for ChondroFiller injection at the patellofemoral joint, and all three are assessed before treatment is offered.

The first is confirmation of cartilage damage on MRI. The injection pathway is open to focal lesions at any ICRS grade and to diffuse wear across the patellar surface — there is no defect-size ceiling and no upper age limit. Unlike arthroscopic or cell-based procedures (such as MACI), which require healthy surrounding cartilage borders and a structurally intact subchondral bone plate, the injectable scaffold is delivered as an outpatient procedure that can coat the entire articular surface in a single session. This makes it relevant to the post-dislocation chondral lesion in a 22-year-old and to the diffuse Grade III wear in a 60-year-old alike, provided the other candidacy conditions are met.

The second condition is mechanical stability. The scaffold cannot compensate for ongoing biomechanical overload: where patellar maltracking, significant malalignment, or untreated ligament instability is driving the cartilage damage, that must be corrected concurrently or as a prior step. Injecting a collagen scaffold into a mechanically hostile environment risks failure of the repair process regardless of how well the injection is performed — a principle that holds across all cartilage restoration techniques.

The third condition is a realistic regenerative timeline. New cartilage matrix develops over six to twelve months as the patient's own progenitor cells migrate into the scaffold; patients who need rapid return to high-impact activity or who cannot commit to that window are unlikely to achieve the full benefit.

One honest boundary: where imaging shows bone-on-bone contact at the patellofemoral joint and the cartilage architecture is effectively exhausted, ChondroFiller injection is unlikely to be the right conversation. That clinical picture moves toward joint preservation surgery or patellofemoral arthroplasty — a distinction a consultant assessment will clarify.

How ChondroFiller injection works as a regenerative scaffold

ChondroFiller is best understood not as a drug or a filler, but as a biological scaffold — a temporary structural framework that gives the body somewhere to build.

The product itself is acellular: it contains no donor cells, no externally added growth factors, and requires no tissue matching or two-stage biopsy procedure. What it contains is a purified murine Type I collagen matrix — the same structural protein that forms the foundation of healthy articular cartilage — formulated as an injectable liquid. Once placed into a cartilage defect, the collagen gels in situ within minutes, conforming to the shape of the lesion and adhering to the defect surface.

That stable matrix then acts as a chemotactic signal: it attracts the patient's own mesenchymal progenitor cells from the surrounding tissue and synovial fluid. Over a six-to-twelve month window, those migrating cells mature into chondrocytes and begin laying down new cartilage matrix — a process termed matrix-induced chondrogenesis. As the new tissue forms, the collagen scaffold progressively biodegrades and is replaced by the patient's own repair tissue. The patient contributes the biology; the product contributes the architecture.

This is mechanistically distinct from what other knee injections do. Hyaluronic acid supplements joint fluid and reduces friction but does not address the defect itself. Corticosteroids suppress inflammation — useful for symptom control, but not regenerative. Arthrosamid (polyacrylamide hydrogel) integrates into the synovial lining and provides mechanical cushioning, again without promoting tissue repair. ChondroFiller injection is the only option in this treatment hierarchy that targets the cartilage tissue directly, aiming to restore it rather than manage the environment around it.

The product is CE-marked as a Class III medical device and manufactured by Meidrix Biomedicals GmbH in Germany — a regulatory classification that reflects the active biological role it plays in tissue repair, rather than a passive lubricant or cushioning function.

The injection appointment: from MRI review to treatment in one visit

Most patients who reach this stage expect a surgical pathway. In practice, the ChondroFiller injection appointment is an outpatient visit — no general anaesthetic, no surgical incision, no overnight stay — that typically runs around one hour from the moment imaging is reviewed to the moment the needle is withdrawn.

The appointment begins with an MRI review. Scans already obtained are assessed to confirm the location, grade, and extent of the patellar cartilage defect and to map where the scaffold needs to be placed. For most patellofemoral presentations, MRI gives a sufficient picture; where prior imaging is unavailable or a clearer real-time view of the joint surface is needed, this will already have been clarified at the pre-treatment consultation stage.

With the defect mapped, the injection itself is delivered under real-time ultrasound guidance — the clinician positions the needle directly at the lesion on the underside of the kneecap and places the collagen liquid precisely into the defect. There is no dry-joint preparation, no theatre booking, and no requirement for the patient to be sedated. As described in the previous section, the scaffold gels within minutes once in contact with the joint environment, conforming to the defect and beginning the biological process that follows.

Box volume is determined at consultation after MRI review. Most isolated patellar lesions are covered by a single box of ChondroFiller; larger defects or cases involving more than one compartment may require two or three. Each package is inclusive of all procedural components — ultrasound, IV antibiotic cover, and a six-week follow-up appointment — so there are no additional procedural costs to anticipate.

For a specific sub-group — patients with a single, contained focal patellar defect in an otherwise structurally healthy joint — a keyhole surgical alternative called Liquid Cartilage™ may also be discussed at consultation. This pathway combines ChondroFiller with mesenchymal stem cell co-delivery in a single procedure. It is not the default: for the majority of patellofemoral presentations, the outpatient injectable route is the appropriate starting point, and the Liquid Cartilage option is raised only where the clinical picture specifically supports it.

Outcomes and what the evidence currently shows

Published cohort data on ChondroFiller injection in the knee shows consistent findings across two validated outcome measures. In a prospective post-market clinical follow-up study by Jerosch et al., IKDC scores improved by a mean of 32.4 points, a gain sustained at three-year follow-up and bringing patients to a functional score of approximately 80. That improvement exceeds the Minimal Clinically Important Difference of 16.7 points — the threshold at which a change in function is considered meaningful to the patient, not just statistically detectable. Serial MRI assessed with the MOCART scoring system confirmed defect filling above 80% at one year, with scores ranging from 81.6 to 84.3, indicating good integration of repair tissue with the surrounding native cartilage.

The safety profile is consistent with the acellular design: published data document a complaint rate of approximately 0.06%, and because the scaffold contains no donor cells, the biological rejection risk associated with cell-based techniques does not apply.

The honest qualification is that this evidence is cohort-level, not randomised controlled trial level. No published RCT has yet examined ChondroFiller injection outcomes specifically in the patellofemoral compartment via the ultrasound-guided injectable route. That gap is worth naming: clinical claims at the kneecap should be held at cohort-study confidence rather than RCT confidence.

For perspective on where ChondroFiller injection sits relative to surgical alternatives: MACI carries randomised trial data — the SUMMIT trial showed superiority over microfracture at five years for defects of 3 cm² or more — and OATS carries longer-term cohort evidence. Both are considerably more invasive: theatre-based, often two-stage, and associated with materially higher reoperation rates. ChondroFiller injection is less demanding on the patient while offering a regenerative mechanism that lubricating or anti-inflammatory injections cannot replicate.

Outcomes are tracked using IKDC scores and MOCART MRI at serial imaging intervals. The clinic holds ICRS Teaching Centre of Excellence status, a designation linked to published outcome data and structured clinical measurement — meaning patients can examine aggregate results rather than relying on anecdotal reporting.

Getting assessed at Lincolnshire Knee

Lincolnshire Knee operates as a sister clinic to the London Cartilage Clinic within the MSK Doctors group, offering consultant-led access to the same ChondroFiller injection pathway — without a GP referral. Clinic sites are at Sleaford NG34, which houses the group's Open MRI and Regeneration Hub, and at Grantham NG31 for consultation and diagnostics.

Assessment follows the sequence described in earlier sections: a consultant review, MRI analysis — where indicated, supported by onMRI AI-driven cartilage segmentation for precise defect mapping — and a candidacy discussion before any treatment decision is reached. Patients with more complex presentations, such as significant malalignment, multi-compartment damage, or a history of prior procedures, receive a full pathway discussion rather than an immediate single-treatment recommendation.

Treatment is entirely self-funded. UK pricing for the ChondroFiller injection ranges from £3,000 for a single box to £8,000 for three, inclusive of consultation, ultrasound guidance, the product, IV antibiotic cover, and a six-week follow-up appointment.

For patients who have spent months managing kneecap pain without an imaging diagnosis or a clear restorative option, a consultant assessment is a practical next step — one that establishes whether the cartilage can still support regeneration and what an appropriate treatment sequence looks like. Book at lincolnshireknee.co.uk.